Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 19, 2024 (filed on Apr 19, 2024)Insider Name:Duarte IraOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-3,874Price:--
-
Apr 19, 2024 (filed on Apr 19, 2024)Insider Name:Duarte IraOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-1,122Price:$2.64
-
Apr 19, 2024 (filed on Apr 19, 2024)Insider Name:Duarte IraOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:3,874Price:--
-
Apr 19, 2024 (filed on Apr 19, 2024)Insider Name:Forbes William POwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-3,874Price:--
-
Apr 19, 2024 (filed on Apr 19, 2024)Insider Name:Forbes William POwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:3,874Price:--
-
Apr 19, 2024 (filed on Apr 19, 2024)Insider Name:Collard Craig AOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:13,797Price:--
-
Apr 03, 2024 (filed on Apr 05, 2024)Insider Name:Collard Craig AOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-62,500Price:--
-
Apr 03, 2024 (filed on Apr 05, 2024)Insider Name:Collard Craig AOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:62,500Price:--
-
Jan 19, 2024 (filed on Jan 19, 2024)Insider Name:Christian WaageOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:83,685Price:--
-
Jan 19, 2024 (filed on Jan 19, 2024)Insider Name:Christian WaageOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:13,948Price:--
Filings by filing date
-
Apr 19, 2024 (filed on Apr 19, 2024)Insider Name:Duarte IraOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-3,874Price:--
-
Apr 19, 2024 (filed on Apr 19, 2024)Insider Name:Duarte IraOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-1,122Price:$2.64
-
Apr 19, 2024 (filed on Apr 19, 2024)Insider Name:Duarte IraOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:3,874Price:--
-
Apr 19, 2024 (filed on Apr 19, 2024)Insider Name:Forbes William POwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-3,874Price:--
-
Apr 19, 2024 (filed on Apr 19, 2024)Insider Name:Forbes William POwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:3,874Price:--
-
Jan 19, 2024 (filed on Apr 19, 2024)Insider Name:Collard Craig AOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-13,797Price:--
-
Apr 19, 2024 (filed on Apr 19, 2024)Insider Name:Collard Craig AOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:13,797Price:--
-
Apr 03, 2024 (filed on Apr 05, 2024)Insider Name:Collard Craig AOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-62,500Price:--
-
Apr 03, 2024 (filed on Apr 05, 2024)Insider Name:Collard Craig AOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:62,500Price:--
-
Jan 19, 2024 (filed on Jan 19, 2024)Insider Name:Christian WaageOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:83,685Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 4242 Campus Point Court, Suite 200 SAN DIEGO CA 92121 |
Tel: | N/A |
Website: | https://www.herontx.com |
IR: | See website |
Key People | ||
Adam Morgan Chairman of the Board | Lisa Peraza Vice President | Craig Alexander Collard Chief Executive Officer, Director |
Ira Duarte Chief Financial Officer, Principal Accounting Officer | William P. Forbes Executive Vice President, Chief Development Officer | Thomas B. Ottoboni Senior Vice President - Pharmaceutical and Translational Sciences, Chief Scientific Officer |
Sean T. Ristine Senior Vice President of Human Resources | Robert Sullivan Senior Vice President | Jason Grillot Vice President of Sales and Marketing | John Arthur Vice President - Manufacturing and Supply |
Business Overview |
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States. |
Financial Overview |
For the fiscal year ended 31 December 2023, Heron Therapeutics Inc revenues increased 18% to $127M. Net loss decreased 39% to $110.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects "Research and development - Balancing va decrease of 65% to $19.8M (expense), Sales and marketing - Balancing value decrease of 16% to $58.1M (expense). |
Employees: | 126 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $465.95M as of Dec 31, 2023 |
Annual revenue (TTM): | $127.04M as of Dec 31, 2023 |
EBITDA (TTM): | -$107.72M as of Dec 31, 2023 |
Net annual income (TTM): | -$110.56M as of Dec 31, 2023 |
Free cash flow (TTM): | -$60.33M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $69.08M as of Dec 31, 2023 |
Shares outstanding: | 150,328,585 as of Feb 28, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |